William Wong, MD
Ophthalmology · Aiea, HINPI 1144270042
Payments from drug & device makers
Across 532 payments — averaging $75.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$11K
- Alcon$8K
- Johnson & Johnson Surgical Vision, Inc.$4K
- Glaukos Corporation$4K
- AbbVie$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- plus $10K from 25 others
What the payments were for
- Consulting fees$4,78212%
- Speaking & faculty fees$8,30021%
- Travel & lodging$3,3258%
- Food & beverage$23,08557%
- Other$8382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 42 | $11,160 |
| Alcon | 66 | $7,577 |
| Johnson & Johnson Surgical Vision, Inc. | 41 | $3,835 |
| Glaukos Corporation | 19 | $3,512 |
| AbbVie(2 entities) | 88 | $2,314 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $1,992 |
| Amgen(2 entities) | 43 | $1,729 |
| Sight Sciences, Inc. | 21 | $1,483 |
| Dompe US, Inc. | 24 | $1,112 |
| Sun Pharmaceutical Industries Inc. | 23 | $710 |
| Rxsight Inc | 10 | $613 |
| Oyster Point Pharma, Inc. | 19 | $575 |
| Tarsus Pharmaceuticals, Inc. | 20 | $462 |
| Genentech USA, Inc. | 3 | $394 |
| Mallinckrodt Hospital Products Inc. | 7 | $381 |
| Novartis | 15 | $366 |
| Aerie Pharmaceuticals, Inc. | 14 | $339 |
| ANI Pharmaceuticals, Inc. | 12 | $337 |
| Kala Pharmaceuticals, Inc. | 17 | $321 |
| Dutch Ophthalmic, USA | 2 | $207 |
| Regeneron Healthcare Solutions, Inc. | 1 | $132 |
| Ivantis, Inc | 4 | $125 |
| Mallinckrodt Enterprises LLC | 6 | $117 |
| Beaver-visitec International, Inc. | 1 | $115 |
| Apellis Pharmaceuticals, Inc. | 1 | $112 |
| Galderma Laboratories, L.p. | 1 | $100 |
| Biotissue Holdings Inc. | 2 | $90 |
| Shire North American Group Inc | 3 | $49 |
| NEW World Medical,inc. | 1 | $29 |
| Heidelberg Engineering, Inc. | 1 | $25 |
| Staar Surgical Company | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$12,677
- enVista Aspire IOL$5,400
- LenSx$3,191
- Tecnis Symfony IOL$1,438
- Tecnis IOL$1,421
- Unity$1,113
- OMNI(R) SURGICAL SYSTEM (US)$1,018
- TEPEZZA$916
- STELLARIS$891
- Oxervate$729
- Clareon$599
- XEN GLAUCOMA TREATMENT SYSTEM$503
- VYZULTA$498
- ARGOS$493
- CATALYS SYSTEM$429
- iDoseTR$387
- RXSIGHT CONTACT LENS$363
- RXSIGHT INJECTOR CARTRIDGE$363
- RXSIGHT INJECTOR HANDPIECE$363
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$363
How this compares
$40,330 in reported general payments places this provider in the 90th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 73 | $99,820 |
| XiidraLifitegrast | 62 | $91,209 |
| VyzultaLatanoprostene Bunod | 137 | $69,735 |
| RocklatanNetarsudil Mesylat/Latanoprost | 88 | $46,890 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $28,734 |
| CequaCyclosporine | 23 | $28,260 |
| RhopressaNetarsudil Mesylate | 52 | $27,126 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 66 | $19,313 |
| LumiganBimatoprost | 27 | $18,546 |
| MieboPerfluorohexyloctane/Pf | 22 | $16,860 |
| ZyletTobramycin/Lotepred Etab | 19 | $7,646 |
| Brimonidine Tartrate | 59 | $7,616 |
| Lotemax SmLoteprednol Etabonate | 24 | $7,181 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $6,347 |
| Bromfenac Sodium | 37 | $6,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $11,160 | $177,804221 claims |
| AbbVieRestasis, Combigan, Lumigan | $2,314 | $147,100138 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $339 | $74,016140 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $710 | $28,26023 claims |
| AlconSimbrinza | $7,577 | $19,31366 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Lotemax Sm, Loteprednol Etabonate | $1,992 | $18,31057 claims |
| NovartisIlevro | $366 | $4,39012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Aiea
- Raymond WeeAiea$2.4M
- Gregg KokameAiea$1.1M
- James LaiAiea$430K
- Sarah ReadAiea$169K
- Luis OmphroyAiea$25K
- Kenneth LeeAiea$3K
- Carlton YuenHonolulu$440K
- Neda NikpoorHonolulu$322K
- Alan FaulknerHonolulu$207K
- Michael BennettHonolulu$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.